Hair restoration has moved through three broad ideas in the last decade: replace what is missing, stimulate what is there, and — most recently — change the signals the follicle is receiving. That third idea is where secretome research sits.
This is an emerging field, not a settled one. Here is what is actually known, what is still being studied, and how to think about it without the marketing.
Start With the Word Itself
Secretome = everything a cell secretes. In this context: growth factors, cytokines, extracellular vesicles (exosomes among them), and microRNA that carries signalling instructions between cells.
Critically, a secretome preparation is cell-free. The stem cells used in the laboratory process are removed; what remains is the mixture of factors they released. This is why calling it "stem cell hair treatment" is inaccurate — the therapeutic interest is in cell communication, not cell transplantation.
In Canada, treatments involving living cells fall under a distinct and considerably stricter regulatory framework. Secretome preparations for hair are not an approved hair-loss treatment here, and any discussion of them belongs in an educational and assessment context — which is exactly how we treat the topic at SkinArtMD.
What the Follicle Is Actually Doing
The follicle is one of the few adult structures that cycles through growth and regression throughout life:
- Anagen — active growth, lasting years on the scalp
- Catagen — a short regression phase
- Telogen — rest
- Exogen — release of the old shaft
Progressive thinning is usually a shortening of anagen combined with follicle miniaturization: the hair produced becomes finer, shorter and lighter with each cycle until it no longer reaches meaningful length. The follicle is often still present — just producing less.
The dermal papilla at the follicle base coordinates this cycling, and it is signal-responsive. That responsiveness is the entire premise behind studying concentrated signalling factors for hair. It is a coherent hypothesis with growing preliminary evidence — and it is not the same thing as proof of clinical benefit.
PRP, Exosomes, Secretome: Where Each Sits
These get used interchangeably in marketing. They are not the same.
| Contents | Origin | Track record | |
|---|---|---|---|
| PRP | Concentrated platelets and their growth factors | Autologous — your own blood | Longest clinical use of the three |
| Exosome preparations | Extracellular vesicles with signalling cargo | Plant-derived at our clinic | Newer |
| Secretome | Broader mixture: factors, vesicles, miRNA | Laboratory-processed, cell-free | Newest, least long-term data |
Note the pattern: novelty correlates with less evidence, not more. A newer category is a reason for careful expectation-setting, not automatic preference.
Why Timelines Are Long — And Why That Is Normal
Patients frequently expect visible change in weeks. Follicle biology does not work that way.
A follicle that re-enters an active growth phase still has to produce a shaft, and that shaft has to grow long enough to be visible and to change how density looks. Roughly a centimetre a month is the realistic pace. This is why:
- 3–6 months is the honest evaluation window
- Standardized photography matters more than impressions in a mirror
- A course of sessions is normal, since signalling responds to repeated input
- Maintenance is expected — it is not evidence the approach failed
Any provider offering visible results in weeks is describing marketing, not hair biology.
The Patterns We Assess in Burnaby
Dr. Sharon Fong (CPSBC) sees hair concerns arriving through several distinct routes:
- Androgenetic thinning — the most common, and the most responsive to early action
- Postpartum shedding — usually self-limiting; reassurance and monitoring often beat intervention
- Perimenopausal and menopausal changes — hormonal shifts altering the growth phase
- Shedding after rapid weight loss, including with GLP-1 class medications
- Telogen effluvium after illness, surgery, or acute stress — often reversible once the trigger resolves
- Scalp conditions — seborrheic dermatitis and inflammatory conditions that must be treated first
Some of these need treatment. Some need time. Some need a dermatology referral. Distinguishing between them is the single most valuable step, and it cannot be done from a product page.
What a Responsible Consultation Covers
- History and pattern — onset, rate, distribution, family history
- Scalp examination — inflammation, scaling, evidence of scarring
- Blood work when indicated — thyroid, ferritin/iron studies, hormonal markers
- Temporary versus progressive — this determines everything downstream
- A frank conversation about evidence — including where evidence is thin
If a clinic skips step 5, that is informative in itself.
Frequently Asked Questions
Is secretome the same as a stem cell transplant? No. Secretome preparations are cell-free — the cells are removed during processing and only their secreted factors remain. Living-cell therapies are regulated very differently in Canada.
Is it approved for hair loss in Canada? No. It is an emerging research area. We discuss it educationally, and any decision follows a physician assessment.
Is it better than PRP? There is no basis to claim that. PRP has the longest clinical track record of the options discussed here. Newer does not mean superior.
How soon would changes be visible? Hair grows roughly a centimetre a month, so 3–6 months is the realistic window for any follicle-directed approach — assessed with standardized photography.
Do you offer consultations in Chinese? Yes — consultations at SkinArtMD Burnaby are available in English, Mandarin and Cantonese, steps from Metrotown SkyTrain.
If You Are Noticing Thinning
The most useful first move is not selecting a treatment — it is establishing what kind of hair loss you have. Book an assessment with Dr. Fong, and we will start there.
Important: This article is for education only and is not medical advice. Stem-cell-derived secretome preparations for hair are an emerging area; they are not an approved treatment for hair loss in Canada, evidence is still developing, and individual responses vary. Treatment decisions are made with a physician after an in-person assessment.
